{"id":"W4399509789","doi":"10.1093/ndt/gfae132","title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","year":2024,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Institutes of Health; Akebia Therapeutics; Vifor Pharma; Astellas Pharma; Impulse Dynamics; Novo Nordisk; ReCor Medical; National Medical Research Council; Ingham Institute for Applied Medical Research; Cytokinetics; Genesis Pharma; Vertex Pharmaceuticals; Boston Scientific Corporation; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; Sanofi; American Society of Nephrology; Medical Research Council; Bayer; Victor Chang Cardiac Research Institute; Amgen","keywords":"Medicine; Kidney disease; Internal medicine; Renal function; Randomized controlled trial; Diabetes mellitus; Tolerability; Placebo; Type 2 diabetes; Adverse effect; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005080399,0.0001336474,0.0005618524,0.0002789311,0.0000271428,0.000005581982,0.00005047063,0.00006790552,0.00004758833],"category_scores_gemma":[0.0005268452,0.00007097955,0.00009637432,0.0003675083,0.0001553794,0.00004501708,0.000006902365,0.0001180126,6.294762e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004210809,"about_ca_system_score_gemma":0.0005638616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001349883,"about_ca_topic_score_gemma":0.00001193362,"domain_scores_codex":[0.9983172,0.0004817816,0.0005131622,0.0002076778,0.0003666307,0.0001135861],"domain_scores_gemma":[0.9988318,0.00051116,0.0001519683,0.0001754138,0.0001609975,0.0001686747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9773442,0.000314429,0.01168075,0.0006972916,0.000103372,0.00001433374,0.001082181,0.0005435207,0.002684585,0.000110161,0.00008657466,0.005338581],"study_design_scores_gemma":[0.3660351,0.002388533,0.6083469,0.003041038,0.002287103,5.292219e-7,0.00001323163,0.01551192,0.002076637,0.00006094195,0.0001021289,0.0001359432],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932287,0.00009512933,0.001605626,0.002057986,0.00006185659,0.002483294,0.0004521142,0.000006924063,0.000008387077],"genre_scores_gemma":[0.9981339,0.0001546575,0.0001258109,0.0004309246,0.00003458077,0.0001499382,0.0009526409,0.00001288654,0.000004666658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6113091,"threshold_uncertainty_score":0.2894462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007129561595460208,"score_gpt":0.2410019234860091,"score_spread":0.2338723618905489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}